These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 3481247)
1. Disk diffusion susceptibility testing of the Bacteroides fragilis group. Horn R; Bourgault AM; Lamothe F Antimicrob Agents Chemother; 1987 Oct; 31(10):1596-9. PubMed ID: 3481247 [TBL] [Abstract][Full Text] [Related]
2. Development of EUCAST disk diffusion method for susceptibility testing of the Bacteroides fragilis group isolates. Nagy E; Justesen US; Eitel Z; Urbán E; Anaerobe; 2015 Feb; 31():65-71. PubMed ID: 25464140 [TBL] [Abstract][Full Text] [Related]
3. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Appelbaum PC; Spangler SK; Jacobs MR Antimicrob Agents Chemother; 1990 Aug; 34(8):1546-50. PubMed ID: 2221864 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Stratton CW; Weeks LS; Aldridge KE Diagn Microbiol Infect Dis; 1991; 14(5):377-82. PubMed ID: 1797454 [TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group. Bourgault AM; Lamothe F J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324 [TBL] [Abstract][Full Text] [Related]
6. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain. García-Rodríguez JE; García-Sánchez JE Rev Infect Dis; 1990; 12 Suppl 2():S142-51. PubMed ID: 2305180 [TBL] [Abstract][Full Text] [Related]
7. Survey of Bacteroides fragilis group susceptibility patterns in Canada. Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600 [TBL] [Abstract][Full Text] [Related]
8. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. Goldstein EJ; Citron DM; Cherubin CE; Hillier SL J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570 [TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of the Bacteroides fragilis group in community hospitals. File TM; Thomson RB; Tan JS; Salstrom SJ; Jacobs GA; Johnson L; Tan L Diagn Microbiol Infect Dis; 1986 Nov; 5(4):317-22. PubMed ID: 3465493 [TBL] [Abstract][Full Text] [Related]
10. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group. Goldstein EJ; Citron DM J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664 [TBL] [Abstract][Full Text] [Related]
11. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents. Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes. Werner H; Heizmann W; Luft G Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438 [TBL] [Abstract][Full Text] [Related]
14. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units. Gill CJ; Ponticas S; Shungu DL; Guerriero S Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725 [TBL] [Abstract][Full Text] [Related]
15. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents. Downes J; Andrew JH Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597 [TBL] [Abstract][Full Text] [Related]
16. Variations in susceptibility to latamoxef(moxalactam) and cefoxitin within the Bacteroides fragilis group. Eley A; Greenwood D J Antimicrob Chemother; 1984 Mar; 13(3):245-55. PubMed ID: 6725175 [TBL] [Abstract][Full Text] [Related]
17. [Sensitivity of anaerobes to 8 antibiotics]. Sedallian A Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):645-7. PubMed ID: 3534760 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Bacteroides non-fragilis and fusobacteria to amoxicillin, amoxicillin/clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem and metronidazole. Jacobs MR; Spangler SK; Appelbaum PC Eur J Clin Microbiol Infect Dis; 1990 Jun; 9(6):417-21. PubMed ID: 2387295 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance. Brown JE; Del Bene VE; Collins CD Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986 [TBL] [Abstract][Full Text] [Related]